Filing Flows › BillionToOne (BLLN) › Q2 2026 › vs Q2 2025
BillionToOne (BLLN) Q2 2026 vs Q2 2025 (year over year)
BillionToOne's revenue rose $42.9M (+64%) from $66.6M in Q2 2025 to $109M in Q2 2026. The biggest changes: Prenatal +$33.4M (+55%); Oncology +$8.7M (+176%); Clinical trial support and other services +$763K (+99%). Gross margin 70.5% against 65.3% (+5.2 pts).
BillionToOne, Q2 2026: revenue $109M (+64% year over year), operating margin 5.0%, net earnings $8.1M, operating cash flow $9.1M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Gross margin | 70.5% | 65.3% | +5.2 pts |
| Operating margin | 5.0% | -2.4% | +7.5 pts |
| Net margin | 7.4% | -0.4% | +7.7 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Prenatal | $94.2M | $60.9M | $33.4M | +55% |
| Oncology | $13.7M | $4.9M | $8.7M | +176% |
| Clinical trial support and other services | $1.5M | $774K | $763K | +99% |
| Revenue | $109M | $66.6M | $42.9M | +64% |
| Gross profit | $77.1M | $43.5M | $33.6M | +77% |
| Cost of revenue | $32.3M | $23.1M | $9.2M | +40% |
| Other income, net | $2.0M | $1.4M | $620K | +44% |
| Operating profit | $5.5M | −$1.6M | $7.1M | — |
| Operating expenses | $71.6M | $45.1M | $26.5M | +59% |
| Pre-tax earnings | $7.5M | −$232K | $7.8M | — |
| Research & development | $17.3M | $11.8M | $5.6M | +47% |
| SG&A | $54.3M | $33.3M | $20.9M | +63% |
| Income tax benefit | $536K | −$14K | $550K | — |
| Net earnings | $8.1M | −$246K | $8.3M | — |
| Operating cash sources | $18.1M | $4.2M | $13.9M | +328% |
| Depreciation & amortization | $1.8M | $1.7M | $82K | +5% |
| Share-based compensation | $8.2M | $2.7M | $5.5M | +201% |
| Working capital & other | $9.0M | $3.1M | $5.9M | +194% |
| Operating cash flow | $9.1M | $1.2M | $8.0M | +673% |
Questions
How much did BillionToOne's revenue grow year over year in Q2 2026?
BillionToOne's revenue rose $42.9M (+64%) from $66.6M in Q2 2025 to $109M in Q2 2026.
What drove BillionToOne's revenue change in Q2 2026?
Prenatal +$33.4M (+55%); Oncology +$8.7M (+176%); Clinical trial support and other services +$763K (+99%).